Short Interest Worth Watching: What’s Propelling Ascendis Pharma A/S Ads (NASDAQ:ASND) After Lower Shorts Reported?

November 24, 2016 - By kentuckypostne   ·   0 Comments

Short Interest Worth Watching: What’s Propelling Ascendis Pharma A/S Ads (NASDAQ:ASND) After Lower Shorts Reported?

The stock of Ascendis Pharma A/S Ads (NASDAQ:ASND) registered a decrease of 10.98% in short interest. ASND’s total short interest was 424,900 shares in November as published by FINRA. Its down 10.98% from 477,300 shares, reported previously. With 203,400 shares average volume, it will take short sellers 2 days to cover their ASND’s short positions. The short interest to Ascendis Pharma A/S Ads’s float is 4.77%. The stock increased 0.68% or $0.14 on November 23, hitting $20.62. About 33,098 shares traded hands. Ascendis Pharma A S (NASDAQ:ASND) has risen 17.18% since April 22, 2016 and is uptrending. It has outperformed by 11.77% the S&P500.

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The company has a market cap of $652.41 million. The Firm is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. It currently has negative earnings. The Firm is developing its product candidate, TransCon human growth hormone for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

ASND Company Profile

Ascendis Pharma A/S, incorporated on October 21, 2006, is a clinical-stage biopharmaceutical company. The Firm is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Firm is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. The Company’s subsidiaries include Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma, Osteoarthritis Division A/S (Denmark) and Ascendis Pharma, and Circulatory Diseases Division A/S (Denmark).

More notable recent Ascendis Pharma A S (NASDAQ:ASND) news were published by: Prnewswire.com which released: “Ascendis Pharma A/S Announces Participation in Two Upcoming Investor Conferences” on November 02, 2016, also Prnewswire.com with their article: “Ascendis Pharma A/S Announces R&D Update to Review Expanded Pipeline and Long …” published on August 15, 2016, Prnewswire.com published: “Ascendis Pharma A/S Appoints Scott T. Smith as Chief Financial Officer” on August 08, 2016. More interesting news about Ascendis Pharma A S (NASDAQ:ASND) were released by: Prnewswire.com and their article: “Ascendis Pharma A/S Reports Second Quarter 2016 Financial Results and Provides …” published on August 31, 2016 as well as Prnewswire.com‘s news article titled: “Ascendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth …” with publication date: August 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By kentuckypostne


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>